Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease

John A. McIntyre, Curtis J. Ramsey, Bruce D. Gitter, Andrew Saykin, Dawn R. Wagenknecht, Paul A. Hyslop

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.

Original languageEnglish
Pages (from-to)344-351
Number of pages8
JournalAutoimmunity
Volume48
Issue number5
DOIs
StatePublished - Aug 1 2015

Fingerprint

Autoantibodies
Alzheimer Disease
Biomarkers
Oxidation-Reduction
Serum
Neuroimaging
Cerebrospinal Fluid
Antiphospholipid Antibodies
Oxidants
Immunoglobulins
Enzyme-Linked Immunosorbent Assay
Demography
Antibodies

Keywords

  • ELISA
  • Mild cognitive impairment
  • Neurodegenerative disease
  • Redox-reactive antiphospholipid autoantibodies
  • Serum biomarkers

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. / McIntyre, John A.; Ramsey, Curtis J.; Gitter, Bruce D.; Saykin, Andrew; Wagenknecht, Dawn R.; Hyslop, Paul A.

In: Autoimmunity, Vol. 48, No. 5, 01.08.2015, p. 344-351.

Research output: Contribution to journalArticle

McIntyre, John A. ; Ramsey, Curtis J. ; Gitter, Bruce D. ; Saykin, Andrew ; Wagenknecht, Dawn R. ; Hyslop, Paul A. / Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. In: Autoimmunity. 2015 ; Vol. 48, No. 5. pp. 344-351.
@article{8aaacf950c61432d9af143547295ffd7,
title = "Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease",
abstract = "A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.",
keywords = "ELISA, Mild cognitive impairment, Neurodegenerative disease, Redox-reactive antiphospholipid autoantibodies, Serum biomarkers",
author = "McIntyre, {John A.} and Ramsey, {Curtis J.} and Gitter, {Bruce D.} and Andrew Saykin and Wagenknecht, {Dawn R.} and Hyslop, {Paul A.}",
year = "2015",
month = "8",
day = "1",
doi = "10.3109/08916934.2015.1008464",
language = "English",
volume = "48",
pages = "344--351",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease

AU - McIntyre, John A.

AU - Ramsey, Curtis J.

AU - Gitter, Bruce D.

AU - Saykin, Andrew

AU - Wagenknecht, Dawn R.

AU - Hyslop, Paul A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.

AB - A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.

KW - ELISA

KW - Mild cognitive impairment

KW - Neurodegenerative disease

KW - Redox-reactive antiphospholipid autoantibodies

KW - Serum biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84942509989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942509989&partnerID=8YFLogxK

U2 - 10.3109/08916934.2015.1008464

DO - 10.3109/08916934.2015.1008464

M3 - Article

C2 - 25672931

AN - SCOPUS:84942509989

VL - 48

SP - 344

EP - 351

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 5

ER -